Zhuhai Livzon Monoclonal Antibody Biotechnology Pharmaceutical Inc.

Zhuhai Livzon Monoclonal Antibody Biotechnology Pharmaceutical Inc.

Zhuhai Livzon Monoclonal Antibody Biotechnology Pharmaceutical Inc. (hereafter referred to as Livzon MABPHARM Inc.) is a biopharmaceutical enterprise that was jointly founded by the Livzon Pharmaceutical Group Inc. and the Joincare Pharmaceutical Group Industry Co., Ltd. in 2010. In order to optimize the company's equity, accelerate the internationalization of its business, attract talent and facilitate financing of the company, Livzon Biologics Hong Kong Limited purchased a 100% stake in Livzon MABPHARM Inc. for RMB 600 million in February 2018. This made Livzon MABPHARM Inc. a wholly owned Hong Kong-Macao-Taiwan enterprise. In March 2018, Livzon MABPHARM Inc. had a registered capital of RMB 533.33 million. In July 2018, Livzon MABPHARM Inc. received Series A funding of USD$148 million. The Livzon Pharmaceutical Group, Joincare Pharmaceutical Group, and Yufeng Fund own 55.13%, 35.75%, and 9.12%, respectively, of Livzon MABPHARM Inc., and the registered capital of Livzon MABPHARM Inc. was approximately RMB 1.13 billion.

The main focus of Livzon MABPHARM Inc. is the research, development, and sales of biopharmaceutical products and antibody drugs, and associated technologies transfer. These include bio-innovative drugs and biosimilar products. The company has a world-class leadership team and first-class innovation and industrialization capabilities.